Metabolic Phenotypes in Childhood Obesity

January 5, 2017 updated by: Peter Adriaensens, Hasselt University

Identification of Metabolic Phenotypes in Childhood Obesity by 1H-NMR Metabolomics of Blood Plasma

This study provides a sound basis towards a better understanding of the biochemical mechanisms behind childhood obesity and its metabolic phenotypes, which will be of great importance towards the development of more personalized prevention and treatment in future.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aim of this study was to identify the plasma metabolic profile associated with childhood obesity and its phenotypes..

This cross-sectional study was set-up to examine the metabolic profile in fasting plasma samples from 65 overweight and obese (OB) children and 37 normal-weight (NW) controls aged 8 to 18 years. The obtained plasma 1H-NMR spectra were rationally divided into 110 integration regions, representing the metabolic phenotype. These integration regions reflect the relative metabolite concentrations and were used as statistical variables to construct a classification model in discriminating between OB and NW children and adolescents. In addition, two metabolic phenotypes were defined within the OB group, i.e. the metabolically "healthy" obese (MHO) and metabolically unhealthy obese (MUO) phenotype which are both classified as obese but with respectively, none (MHO) or at least two components (MUO) of the metabolic syndrome.

Study Type

Observational

Enrollment (Actual)

102

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

65 overweight and obese (OB) children and 37 normal-weight (NW) controls aged 8 to 18 years

Description

Inclusion Criteria:

  • aged 8 to 18
  • normal-weight, overweight or obese according to the International Obesity Task Force (IOTF) Body Mass Index (BMI) criteria
  • fasted for at least 8 hours

Exclusion Criteria:

  • Subjects taking any medication or having serious chronic or acute illness within two weeks preceding the clinical examination,

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
OB-NMR
overweight and obese children and adolescents
Other: Blood sampling
Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
NMR-C
normal-weight children and adolescents
Other: Blood sampling
Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
metabolic phenotype of childhood obesity
Time Frame: day 1
Significant metabolic changes in blood plasma of obese children and adolescents and normal-weight control subjects
day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
metabolic phenotype of metabolically healthy and unhealthy obese children and adolescents
Time Frame: day 1
Significant metabolic changes in blood plasma of metabolically healthy obese and metabolically unhealthy obese children and adolescents
day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hasselt University

Collaborators

Jessa Hospital

Investigators

  • Principal Investigator: Peter Adriaensens, PhD, Institute of Material Research, Hasselt University
  • Study Chair: Guy Massa, PhD, MD, Jessa Ziekenhuis Hasselt
  • Study Chair: Liene Bervoets, PhD, Hasselt University
  • Study Chair: Wanda Guedens, PhD, Institute of Material Research, Hasselt University
  • Study Chair: Gunter Reekmans, Ing, Institute of Material Research, Hasselt University
  • Study Chair: Jean-Paul Noben, PhD, BIOMED, Hasselt University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2012

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

December 13, 2016

First Submitted That Met QC Criteria

January 5, 2017

First Posted (Estimate)

January 9, 2017

Study Record Updates

Last Update Posted (Estimate)

January 9, 2017

Last Update Submitted That Met QC Criteria

January 5, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LCRP-OBNMR

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Pediatric

Clinical Trials on Blood sampling

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe